BMS-986253

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986253 is one of 155 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Immune Checkpoint InhibitionRecruiting

AdenocarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

MelanomaPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Immune Checkpoint InhibitionPhase 2

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Phase 3

6 2

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Phase 3

2 3

HLX07

Shanghai Henlius Biotech

Phase 3

1 4

BMS-986253

Bristol-Myers Squibb

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Melanoma

NCT04572451

Q1 2032

Phase 2Recruiting

Immune Checkpoint Inhibition

NCT03026140

Clinical

Trials by Indication[1]

COVID-191 trial

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Terminated·—·Phase 2·NCT04347226·43 enrolled

Adenocarcinoma1 trial

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02451982·76 enrolled

Non-Small Cell Lung Cancer1 trial

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT04123379·48 enrolled

Immune Checkpoint Inhibition1 trial

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03026140·353 enrolled

Prostate Cancer1 trial

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Active, not recruiting·MMark Stein·Phase 1/2·NCT03689699·59 enrolled

3 more indications

Myelodysplastic Syndromes1 trial

BMS-986253 in Myelodysplastic Syndromes

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT05148234·2 enrolled

Advanced Cancers1 trial

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03400332·281 enrolled

Melanoma1 trial

Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Active, not recruiting·YYana Najjar·Phase 1·NCT04572451·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for BMS-986253. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986253 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986253. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986253

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2032

Trials by Indication[1]

COVID-191 trial

Adenocarcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Immune Checkpoint Inhibition1 trial

Prostate Cancer1 trial

Myelodysplastic Syndromes1 trial

Advanced Cancers1 trial

Melanoma1 trial

References

Drug Info

Quick Facts

Related News